18:36 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Qiming leads series A for Alpha Biopharma

Alpha Biopharma Inc. (Shanghai, China) raised $37 million in the first tranche of a planned $65 million series A round led by Qiming Venture Partners. The TF Fund and LYZZ Healthcare Venture Fund also participated. Alpha...
20:08 , Jun 19, 2018 |  BC Extra  |  Financial News

Qiming leads series A for Alpha Biopharma

Alpha Biopharma Inc. (Shanghai, China) raised $37 million in the first tranche of a planned $65 million series A round led by Qiming Venture Partners. The TF Fund and LYZZ Healthcare Venture Fund also participated. Alpha...
20:14 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

AZ reports data from Phase I BLOOM trial of Tagrisso in NSCLC

AstraZeneca plc (LSE:AZN; NYSE:AZN) reported data from 21 evaluable EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases in the Phase I BLOOM trial showing that oral Tagrisso osimertinib (AZD9291) led to an...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Clinical News

AZD3759: Preliminary Phase I data

Preliminary data from 2 evaluable patients with EGFR mutation-positive NSCLC with brain metastasis in an open-label, dose-escalation, international Phase I trial showed that twice-daily 50 and 100 mg AZD3759 led to 1 unconfirmed partial response...